GP40321 + Apidra® SoloStar® + RinGlar®

Phase 3Completed
0 watching 0 views this week📈 Rising
69
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Type 1 Diabetes Mellitis

Conditions

Type 1 Diabetes Mellitis

Trial Timeline

Apr 14, 2023 → Nov 28, 2023

About GP40321 + Apidra® SoloStar® + RinGlar®

GP40321 + Apidra® SoloStar® + RinGlar® is a phase 3 stage product being developed by GEROPHARM for Type 1 Diabetes Mellitis. The current trial status is completed. This product is registered under clinical trial identifier NCT07070752. Target conditions include Type 1 Diabetes Mellitis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT07070752Phase 3Completed